Ensemble Algorithm Based on Gene Selection, Data Augmentation, and Boosting Approaches for Ovarian Cancer Classification.

Diagnostics (Basel)

Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 235, Taiwan.

Published: December 2024

Ovarian cancer is a difficult and lethal illness that requires early detection and precise classification for effective therapy. Microarray technology has permitted the simultaneous assessment of hundreds of genes' expression levels, yielding important insights into the molecular pathways driving ovarian cancer. To reduce computational complexity and improve accuracy, choosing the most likely differential genes to explain the impacts of ovarian cancer is necessary. Medical datasets, including those related to ovarian cancer, are often limited in size due to privacy concerns, data collection challenges, and the rarity of certain conditions. Data augmentation allows researchers to expand the dataset, providing a larger and more diverse set of examples for model training. Recent advances in machine learning and bioinformatics have shown promise in improving ovarian cancer classification based on gene information. In this paper, we present an ensemble algorithm based on gene selection, data augmentation, and boosting approaches for ovarian cancer classification. In the proposed approach, the initial genetic data were first subjected to feature selection. The target genes were screened and combined with data augmentation and ensemble boosting algorithms. From the results, the chosen ten genes could accurately classify ovarian cancer at 98.21%. We further show that the proposed algorithm based on clustering approaches is effective for real-world ovarian cancer data, with 100% accuracy and strong performance in distinguishing between distinct ovarian cancer subtypes. The proposed algorithm may help doctors identify ovarian cancer patients early and develop individualized treatment plans.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674093PMC
http://dx.doi.org/10.3390/diagnostics14242772DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
44
data augmentation
16
algorithm based
12
based gene
12
cancer classification
12
ovarian
11
cancer
11
ensemble algorithm
8
gene selection
8
selection data
8

Similar Publications

Introduction: Primary cilia play an important role in the development of cancer by regulating signaling pathways. Several studies have demonstrated that women with mutations have, on average, 50% fewer ciliated cells compared with general women. However, the role of tubal cilia loss in the development of epithelial ovarian cancer (EOC) remains unclear.

View Article and Find Full Text PDF

Pleural effusion as an initial presentation of malignancy poses significant diagnostic challenges, particularly when linked to gynecologic cancers. We discuss the case of a 53-year-old female who presented with progressive dyspnea and a massive right-sided pleural effusion. Cytological analysis of the pleural fluid revealed malignant cells and immunohistochemical staining confirmed high-grade serous carcinoma (HGSC) of ovarian origin.

View Article and Find Full Text PDF

Opsoclonus-myoclonus syndrome (OMS) is a rare neurological inflammatory disease of paraneoplastic, parainfectious or idiopathic origin. It is manifested by the occurrence of opsoclonus, myoclonus, ataxia, as well as behavioral and sleep disorders. The incidence is estimated at 1/5,000,000 people.

View Article and Find Full Text PDF

Background: Ovarian cancer is a leading cause of mortality worldwide. The third most prevalent gynecological cancer globally, following cervical and uterine cancer, and the third leading cause of cancer-related mortality among women in Sub-Saharan Africa, including Ethiopia. The time ovarian cancer patients have to wait between diagnosis and initiation of treatment are the indicators of quality in cancer care and influence patient outcomes.

View Article and Find Full Text PDF

Association of blood group types and clinico-pathological features of gynecological cancers (GCs).

BMC Cancer

January 2025

Molecular Diseases & Diagnostics Division, Infinity Biochemistry, Infinity Solutions Unlimited, Sajjad Abad, Chattabal, Srinagar, 190010, Kashmir, India.

Background: Gynecological cancers (GCs) affect the reproductive system of females, and are of multiple types depending on the affected organ most common of which are cervical, endometrial, ovarian cancers. Among different risk factors for GCs, ABO blood group system is considered as one of the pivotal contributing factors for increased susceptibility of GCs. The aim of our study was to report on the demographics of GC patients and to investigate the relationship between the ABO blood group system and the risk of acquiring GC in our population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!